Betalol

Quick links to important sections

Betalol

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Betalol

What is Betalol? (Nebivolol)

Property Description
Active Ingredient Nebivolol hydrochloride
Form Oral Tablet
Pharmacological Class Third-Generation Beta-Adrenergic Blocker
Common Use (General) Supporting cardiovascular function
Origin Synthetic Compound

What is Betalol and What is its Active Ingredient?

Betalol is a pharmaceutical preparation that requires a prescription for use, primarily intended to support the healthy function of the circulatory system. Its active ingredient is the chemically synthesized substance Nebivolol, typically provided in the form of Nebivolol hydrochloride. This medication is administered as an oral tablet dosage form and is definitively classified as a synthetic compound. The Nebivolol molecule itself is a racemic mixture of two stereoisomers, or distinct chemical forms, which work in concert to achieve the drug’s overall therapeutic effects.

What Type of Medicine is Nebivolol?

Nebivolol is classified as a third-generation beta-adrenergic blocker (eta-blocker), belonging to a class of drugs that selectively influence the heart and blood vessels. This categorization distinguishes it from older eta-blockers by its dual mode of operation: it acts as a highly selective eta1-adrenergic receptor antagonist while also possessing unique vasodilatory properties.

What is the General Purpose of Taking a Third-Generation eta-Blocker?

The general purpose of this type of medicine is to support overall cardiovascular function by easing the strain on the circulatory system, a typical use scenario being the long-term management of elevated blood pressure. This is achieved through its ability to slow the heart’s rate and force of contraction (negative chronotropic effect), concurrently promoting the widening of blood vessels, which in turn lowers peripheral vascular resistance. The compound is effective in its dual action of controlling heart activity and promoting peripheral dilation. The overall benefit is the promotion of a normalized and more regulated blood flow.

What side effects are possible with Betalol?

Possible side effects and safety information

The safety profile for Betalol (nebivolol) is officially documented by regulatory agencies and classifies potential effects primarily by frequency and the physiological system affected. Adverse reactions are grouped according to their reported incidence in clinical use, typically defined as common, uncommon, or very rare.

System-Organ Class (SOC) Common Adverse Reactions (Frequency: 1-10 in 100)
Nervous System disorders Headache, Dizziness, Paresthesia
Gastrointestinal disorders Constipation, Nausea, Diarrhea
General disorders Fatigue, Edema

Reactions documented as uncommon (affecting 1 to 10 users in 1,000) include effects on the Cardiac system, such as Bradycardia or heart failure aggravation, Psychiatric disorders like Depression, and Reproductive System effects such as Impotence.

Serious Adverse Reactions officially listed in the product information include Angioedema (a serious allergic reaction), and the aggravation of Psoriasis, both classified as very rare events. Regulatory warnings also note that abrupt discontinuation of the medicine may be followed by a severe exacerbation of symptoms of coronary artery disease.

The use of Betalol is strictly contraindicated (prohibited) in the presence of certain severe pre-existing conditions, including Severe hepatic impairment, Cardiogenic shock, Second and third-degree heart block, and Severe Bradycardia. Furthermore, specific safety notes exist for older adults (those above 70 years), who may experience a higher incidence of Dizziness and Orthostatic hypotension.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe the clinical manifestations of Betalol overdose based on its known pharmacological effects. The most commonly documented signs are bradycardia (abnormally slow heart rate) and hypotension (abnormally low blood pressure). Other documented clinical presentations include dizziness, fatigue, and vomiting.

Severe Outcomes and Emergency Actions

The regulatory profile explicitly warns that overdose may lead to severe and potentially life-threatening outcomes, including cardiac failure, second- or third-degree heart block, bronchospasm, and respiratory failure.

Emergency medical attention is required immediately if an overdose is suspected, especially if these severe manifestations are present. Official guidance is to call the National Poison Control Center for current treatment information. Management involves providing general supportive and specific symptomatic treatment to counteract the specific physiological effects observed, which must be continued until clinical stability is achieved. It is noted that standard procedures like hemodialysis are not expected to enhance clearance of Nebivolol due to the drug’s high protein binding.

Therapeutic Uses of Betalol

Betalol (nebivolol) is commonly used to address conditions presenting with systemic or localized discomfort within the cardiovascular system, providing support that helps ease the overall strain on the heart and blood vessels. This therapeutic approach is relevant for managing essential hypertension (high blood pressure), providing supportive therapy in stable chronic heart failure (especially for older adults), and for easing symptoms of Angina Pectoris (chest pain).

This medication’s core relevance lies in controlling sustained high pressure and supporting patients facing chronic cardiac functional stress, which contributes to maintaining stability in conditions involving heightened systemic burden.

“This support may assist with maintaining functional stability and is relevant for easing symptoms that interfere with daily functioning in the elderly.”

The medication is applied to address symptoms that create noticeable physiological strain and those that interfere with daily functioning, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.


Quick Fact: Relief for Cardiac Strain
This medication is applied in addressing symptoms linked to organ-specific functional stress and may assist with easing the intensity and occurrence of episodes of chest discomfort associated with angina.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility and Contraindication Summary

Labetalol is indicated for adult patients with hypertension. However, its use is strictly contraindicated and prohibited in patient groups with certain severe cardiac and respiratory conditions, as detailed in official regulatory documents.

Contraindicated Populations (Must Not Use):

  • Patients with bronchial asthma or other obstructive airway diseases.
  • Individuals with overt cardiac failure (decompensated heart failure).
  • Those with greater-than-first-degree heart block or severe bradycardia (slow heart rate).
  • Patients experiencing cardiogenic shock.
  • Individuals with a known hypersensitivity to Labetalol or any component of the formulation.
  • Concomitant use with non-dihydropyridine calcium channel blockers (e.g., verapamil) is also contraindicated.

Age-Related and Restricted Use:

  • Pediatric Use: The safety and efficacy of Labetalol have not been established in the pediatric population, and appropriate studies have not been performed.
  • Condition-Specific Caution: Use requires special caution and close monitoring in patients with a history of heart failure (if well-compensated), diabetes mellitus (as it may mask signs of hypoglycemia), or pheochromocytoma (due to risk of paradoxical blood pressure increase).
  • Liver Injury: If a patient develops laboratory evidence of severe liver injury or jaundice, the medication must be stopped permanently.

What should I know about interactions with other medicines?

The official interaction profile for Betalol (Nebivolol) is defined by pharmacokinetic and pharmacodynamic mechanisms documented in government regulatory labeling. The primary pharmacokinetic concern is CYP2D6-mediated metabolism, where co-administration with enzyme inhibitors, such as Fluoxetine or Cimetidine, substantially increases the systemic exposure and plasma levels of the active nebivolol isomer.

Interaction Category Documented Official Outcome
Cardio-depressant Medicines Co-administration with Calcium Channel Blockers (Verapamil or Diltiazem-type), Digitalis Glycosides, or Antiarrhythmics may cause excessive reduction in heart rate and contractility, increasing the risk of bradycardia and hypotension.
Antihypertensive Agents Combination with Centrally-acting Antihypertensives (e.g., Clonidine) can worsen underlying conditions, and abrupt withdrawal of the central agent may risk rebound hypertension. NSAIDs may reduce the intended antihypertensive effect through antagonism.

The drug's absorption is not significantly affected by food, and regulatory documents do not specify mandatory timing separation rules relative to meals. A population-specific caution exists for diabetic patients, as the drug may mask the signs of hypoglycemia, particularly tachycardia, which is noted in the official prescribing information. The profile establishes clear constraints, classifying certain cardio-depressant combinations as strongly cautioned or "not recommended" by regulatory authorities.

Mechanism of Action

Selective Inhibition of Cardiac Sympathetic Signaling

This mechanistic domain involves the drug's primary action as a highly selective competitive antagonist at the boldsymbolbeta1-adrenergic receptor in the heart. By blocking the binding of excitatory catecholamines, this mechanism directly inhibits the transmission of sympathetic signals to the heart muscle. This molecular action initiates a cascade that leads to a reduction in the heart’s speed and pumping force, which consequently alters the inherent rate and force of myocardial contraction.


Endothelium-Driven Vasodilation via Nitric Oxide

The drug possesses a unique secondary mechanism targeting the vascular system by activating the enzyme Endothelial Nitric Oxide Synthase (mathbfeNOS) within the blood vessel lining. This action promotes the synthesis and release of Nitric Oxide (mathbfNO), a key local mediator that causes the surrounding vascular smooth muscle to relax. The resulting physiological effect is the widening of the arterioles, which lowers the overall systemic resistance to blood flow.


Concerted Action of Stereoisomers and Pathway Modulation

Betalol is composed of two chemical forms (stereoisomers) that work in synergy: one primarily provides the cardiac boldsymbolbeta1 antagonism, and the other facilitates the mathbfNO-mediated vasodilation. This dual mechanism also includes the suppression of renin release from the kidneys, acting as an upstream regulator of the Renin-Angiotensin-Aldosterone System (RAAS). These combined effects achieve a concerted, multi-pathway modulation of cardiovascular regulatory systems.

Dosage and Administration Information

The administration of Betalol is based on a structured, once-daily schedule and is delivered solely via the oral route as a tablet. This daily dose can be taken with or without food.

The required dosing regimen is determined by the specific condition being managed. For the management of high blood pressure, the typical starting dose is 5 mg once daily. Doses may be adjusted upward in response to clinical status, generally at intervals of no less than two weeks, up to a maximum of 40 mg once daily.

In contrast, when used as supportive therapy for stable chronic heart failure, certain protocols often require starting with a significantly lower dose, such as 1.25 mg once daily. This dose is gradually increased over several weeks, following a defined titration schedule, up to a maximum of 10 mg once daily.

Official instructions also specify adjustments for certain patient populations. Individuals with severe renal impairment (CrCl < 30 mL/min) or moderate hepatic impairment are typically initiated on a reduced dose of 2.5 mg once daily. In the event a dose is missed, official guidance states that the patient should take the dose as soon as possible, or skip it entirely if the next scheduled dose is near, but the dose should never be doubled. Finally, the overall course of use is structured by the instruction that treatment must not be stopped suddenly; cessation requires a gradual dose reduction, or tapering, over a period of one to two weeks. These instructions define the standardized application of the approved administration protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Betalol (Nebivolol)

The understanding of Betalol in a clinical context is based on findings from formal research, including large randomized controlled trials (RCTs) and scientific summaries from regulatory bodies. Research provides context but not individual predictions.


Evidence for use in Essential Hypertension

Research protocols for Betalol included numerous short-term RCTs. These studies research examined how the medicine compared to a placebo and to other active agents. Researchers focused on measuring the outcomes related to systemic or functional imbalance, primarily the change in systolic and diastolic blood pressure (BP) over time, typically within 6 to 12 weeks. Studies monitored measured blood pressure levels, and data show patterns related to measured changes in the groups receiving Betalol compared to the groups receiving placebo.

What is still uncertain is that these core studies mainly looked at blood pressure change, which is a surrogate outcome, but they were not primarily designed or followed long enough to definitively show the difference in long-term effects on outcomes like preventing heart attacks or strokes compared to all other modern blood pressure medications.


Evidence for use in Stable Chronic Heart Failure

A key source of research for this context is a large-scale, long-term RCT known as the SENIORS trial. This research was specifically applied in studies examining patient-reported experiences and major health events in the elderly population. Studies explored a crucial combined measurement: the composite endpoint of all-cause mortality or hospitalization due to heart or blood vessel problems.

The study findings described patterns where the groups receiving Betalol may have been associated with a lower measured occurrence of the combined endpoint compared to the placebo group over the mean follow-up period of 21 months. The research evidence, however, is highly specific to the elderly patient population (age ≥ 70 years) who participated in this trial. There is limited information for younger adults with chronic heart failure. Furthermore, the specific data for the secondary endpoint of all-cause mortality alone was observed in some studies to have low certainty.

Key Studies & References Nebivolol Drug Information (MedlinePlus Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Betalol (FAQ)


Q: What is the main difference between Betalol and other medicines for the same condition?

Betalol is officially classified as a third-generation beta-blocker. Regulatory documents note that in addition to its main action of blocking beta1-receptors in the heart to slow the heart rate, it possesses a secondary mechanism. This unique action is described as helping to promote the widening of blood vessels by increasing the release of Nitric Oxide (NO), which consequently lowers overall resistance to blood flow.

Q: How long does it usually take for Betalol to start working?

According to official product information, the initial therapeutic effect on blood pressure typically becomes apparent after about one to two weeks of consistent treatment. The full or optimal effect is often reached after a period of four weeks of continuous daily use.

Q: Can taking Betalol affect my energy levels?

Yes, official safety information lists Fatigue and Tiredness as a common adverse reaction, meaning it has been reported in up to 1 in 10 people in clinical use. Regulatory information notes this is a potential effect.

Q: What should I do if I feel dizzy after starting Betalol?

Dizziness is listed in the regulatory documents as a common side effect. Regulatory documents describe strategies to manage dizziness, such as sitting or lying down when the feeling occurs. The official product information advises consulting a healthcare provider if side effects are experienced.

Q: Is Betalol a type of beta-blocker or a different class of medicine?

Betalol is definitively classified as a beta-adrenergic blocking agent, which is commonly known as a beta-blocker. Specifically, it is a third-generation selective beta1-adrenergic receptor antagonist, a category defined in official labeling.

Q: Is it true that Betalol is only for heart issues?

No, official indications for Betalol include two main uses. It is prescribed for the treatment of high blood pressure (hypertension) and is also used as supportive therapy for certain patients with mild to moderate chronic heart failure.

Q: How is Betalol different from an ACE inhibitor?

Betalol and ACE inhibitors are different classes of medicine used for cardiovascular conditions. Betalol is a beta-blocker that works by reducing the heart rate and force. An ACE inhibitor works differently, primarily by blocking the body from forming a substance called Angiotensin II to help relax blood vessels.

Q: What is the longest period Betalol has been studied in clinical trials?

Research evidence includes key large-scale, long-term studies, such as the SENIORS trial for heart failure. This specific trial studied the effects of the drug in elderly patients over a mean follow-up period of 21 months, which is a key reference for long-term use.

Q: Is it normal to feel tired in the first few weeks of taking Betalol?

Official reports indicate Fatigue is a common side effect. While the specific timeframe is not always defined in official documents, it is listed as an expected side effect.

Q: Can I take ibuprofen or other common painkillers while on Betalol?

Regulatory documents state that co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes medicines like ibuprofen, is documented. This interaction may reduce the intended blood pressure-lowering effect of Betalol through an antagonistic mechanism.

Q: Does Betalol interact with commonly used herbal supplements?

Regulatory documents detail interactions with specific drug classes but generally advise patients to inform their healthcare provider about all other products used. This includes vitamins, herbal supplements, and non-prescription medicines, as some ingredients may interact and require monitoring or separation of administration times.

Q: What is the standard regulatory classification of Betalol's safety profile?

The safety profile of Betalol is classified by official bodies for special patient groups. For example, it is noted to carry a specific safety classification for use during pregnancy in the US system. It also carries warnings about its potential to mask signs of hypoglycemia (low blood sugar) in diabetic patients.

Q: Does Betalol affect sleep or cause insomnia?

Yes, Insomnia (difficulty falling or staying asleep) is specifically listed in the official safety profile as a reported adverse reaction. This is noted alongside other central nervous system effects described in the product information.

Q: Can Betalol be split in half, according to the manufacturer's directions?

For certain tablet strengths of Betalol, official information from the manufacturer includes specific instructions that show the tablet can be broken along the score line. This feature is intended to allow for obtaining a half-dose if necessary for dose titration.

Q: How do doctors choose the right dose of Betalol for a patient?

Official regulatory instructions state that the dose is titrated (adjusted) individually to patient needs. The choice is primarily based on the condition being treated and the patient’s clinical response, often starting low and increasing gradually over several weeks to reach the proper maintenance dose.

Q: What is the purpose of the different strengths (mg) of Betalol tablets?

The availability of different strengths (e.g., 1.25 mg, 2.5 mg, 5 mg) is defined in official documents to facilitate dose titration. This gradual adjustment is necessary, particularly when treating conditions like chronic heart failure, where treatment must begin at a very low dose and be slowly increased.

Q: Is the evidence for Betalol's use in children strong?

No. Official documents state that the safety and efficacy of Betalol have not been established in the pediatric population. This means appropriate studies involving children under 18 years of age have not been performed.

Q: How long does Betalol stay in the body after the last dose?

According to official pharmacokinetics data, in most people (Extensive Metabolizers), the drug's active compound has an effective half-life of about 12 hours. However, in a smaller group of people (Poor Metabolizers), the half-life is longer, lasting approximately 19 hours.

Q: Can Betalol interact with common cold or flu medicines?

Official documents caution that some common cold or flu medicines contain sympathomimetic agents (such as decongestants). Using Betalol alongside these agents is noted as potentially leading to an increase in blood pressure due to their combined effects on the cardiovascular system.

Q: Does Betalol affect fertility in men or women?

The official safety profile lists Impotence (erectile dysfunction) as an uncommon side effect in men. There is no comparable statement in regulatory documents regarding effects on female fertility.

Q: Are there any official restrictions on driving while taking Betalol?

Official warnings note that adverse reactions such as dizziness and fatigue may occur, especially when starting treatment. Regulatory documents warn that if these effects occur, the ability to drive or operate machinery may be impaired.

Q: Is there a risk of Betalol causing vision changes?

While rare, some official safety information notes a very rare risk of Serious eye symptoms. These symptoms can include issues such as blurred vision or tunnel vision. Official information advises patients who experience these effects to seek medical attention.

Q: Does Betalol affect blood sugar levels?

Official warnings state that Betalol may mask the early warning signs of hypoglycemia (low blood sugar), such as a rapid heartbeat. Official warnings note that diabetic patients may require careful consideration when using this medication.

How should Betalol be stored and disposed of?

How to Store and Dispose of Betalol (Nebivolol) Tablets

The storage of Betalol tablets is regulated to maintain product stability. The medicine must be stored at Controlled Room Temperature, which is defined as 20 to 25 C (68 to 77 F), with excursions permitted up to 30 C.

Storage Requirements

  • Protection: Keep the container tightly closed and protect the medicine from heat and moisture. The tablets must not be frozen.
  • Child Safety: All Betalol tablets must be kept out of the sight and reach of children.
  • Container: Store the medicine only in the original container.

Disposal Instructions

Unused or expired tablets should be disposed of properly according to official guidance. Patients are directed to use a community drug take-back program when available. If a take-back program is not accessible, the tablets must be mixed with an undesirable substance (such as used coffee grounds or dirt) and sealed in a container before being placed in the household trash. Tablets should not be flushed down the toilet or poured down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Betalol found in:

A-Z Index: